BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Yes, but potential future sales revenue isn't the whole story.

Is BioNTech's Coronavirus Vaccine Candidate a Game-Changer for Investors?

AstraZeneca

Moderna

Pfizer

Yes, one or more COVID-19 vaccines could realistically be available before the end of the year.

3 Drugmakers Most Likely to Launch Coronavirus Vaccines in the U.S. by the End of 2020

Distribution issues with these vaccines could be giving investors cold feet, and one has a clear disadvantage.

Why These 3 Coronavirus Stocks Are Falling This Week

ADMA Biologics

Cerus

Liminal BioSciences

Sonnet BioTherapeutics

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Biotech Boom: The Race for COVID-19 Vaccines

However, the ultimate decision will be based on the data the companies submit, he notes.

FDA Willing to Authorize Coronavirus Vaccine Before Phase 3 Trials Are Complete, Agency Head Says

GlaxoSmithKline

Heat Biologics

Inovio Pharmaceuticals

Johnson & Johnson

Novavax

Sanofi

Vaxart

COVID-19 vaccine stocks have gotten slammed this month.

Has The COVID-19 Vaccine Stock Bubble Burst?

Demand says we may need several players crossing the finish line.

In the Race for a Coronavirus Vaccine, Can There Be Multiple Winners?

It has already been granted permission for use by the Chinese military.

China's CanSino Pushing for Early Authorization for COVID-19 Vaccine

BioNTech (BNTX) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

BioNTech (BNTX) Looks Good: Stock Adds 10.2% in Session

Emergent BioSolutions

Either company could win the race to develop a COVID-19 vaccine, but one has an easier path to victory.

Better Coronavirus Stock: BioNTech or Emergent BioSolutions?

Any vaccine designed to prevent COVID-19 will need to do well at protecting older people.

Pfizer and BioNTech's Coronavirus Vaccine Candidate Produces Antibodies in People Up to 85 Years Old

The U.S. drug maker and its partner BioNTech say there are on track to seek regulatory review of their COVID-19 vaccine as early as October 2020 if it is successful in clinical trials.

Pfizer Eyes Vaccine Race Finish Line

Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

The Data Just Keeps Getting Better for Pfizer and BioNTech’s COVID-19 Vaccine

Shares of Pfizer Inc and U.S.-listed shares of partner BioNTech SE rose on Friday after they released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.

Pfizer, BioNTech shares gain as more data backs vaccine candidate

Pfizer Inc (NYSE: PFE), and its partner BioNTech SE (NASDAQ: BNTX), announced positive results for the Phase 1 trial of their second COVID-19 vaccine candidate, stating that the latest vaccine candidate had fewer side effects than their first.

Pfizer, BioNTech Say Second Coronavirus Vaccine Shows Fewer Side Effects Than Their First Candidate

Pfizer and BioNTech surprised many industry watchers on July 27 when they announced they would conduct a large-scale study of a vaccine for Covid-19. The surprise?

Pfizer and BioNTech's favored Covid-19 vaccine has fewer side effects than their first

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S.

Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

Merck

What’s the best way for investors to gain diversified exposure to today's leading vaccine research? Here he recommends a 5-stock portfolio to boost your chances to benefit from potential progress made toward a successful Covid vaccine.

This 5-Stock Portfolio Is A Safe Bet On A Future COVID-19 Vaccine

CureVac B.V

Hope for a successful vaccine by the winter is fueling trials at a record pace.

COVID-19: The Real Results Are A Long Way Away

Vaccine candidates need to garner regulatory approval by Jan. 31, 2021, or else.

Moderna and Other Coronavirus Vaccine Makers to Take Reduced Payments If Approval Milestones Not Met

The federal government will foot the bill for vaccines, while insurers and the CARES Act will cover the cost of administering them.

Coronavirus Vaccine Will Be Free for Americans, Says HHS Official

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in BioNTech (BNTX) Stock?

The U.S. has doled out billions to develop a vaccine against the coronavirus, locking in a minimum of 800 million doses so far.

The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals stand

BioNTech SE (BNTX) CEO Ugur Sahin on Q2 2020 Results - Earnings Call Transcript

It's a tight schedule, but it could mean the duo gains regulatory approval first.

News for BioNTech SE Stock (BNTX)